Cargando…
Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
BACKGROUND: Immune checkpoint inhibitors (ICIs) represent a promising novel class of cancer therapy, but immune-mediated adverse events can complicate ICI treatment. Acute cholecystitis in patients receiving ICI therapy has not been characterized. We aimed to describe the clinical features of patien...
Autores principales: | Abu-Sbeih, Hamzah, Tran, Cynthia Nguyen, Ge, Phillip S., Bhutani, Manoop S., Alasadi, Mazen, Naing, Aung, Jazaeri, Amir A., Wang, Yinghong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499962/ https://www.ncbi.nlm.nih.gov/pubmed/31053161 http://dx.doi.org/10.1186/s40425-019-0604-2 |
Ejemplares similares
-
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019) -
Patients with breast cancer may be at higher risk of colorectal neoplasia
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019) -
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019) -
Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2018) -
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
por: Wang, Yinghong, et al.
Publicado: (2018)